ADAP - Why Adaptimmune Therapeutics (ADAP) Stock Is Moving | Benzinga
Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) shares are trading higher by 15.8% to $1.17 during Friday’s session after the company and Galapagos entered a clinical collaboration to license Adaptimmune’s uza-cel in head & neck cancer.
Uza-cel, which has shown an 80% response rate in a Phase 1 trial, is engineered to express the CD8? co-receptor, enhancing the immune response against tumors.
The collaboration will utilize Galapagos’ decentralized cell manufacturing platform, which ...
ADAP) Stock Is Moving>Full story available on Benzinga.com